sorafenib has been researched along with fasentin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (fasentin) | Trials (fasentin) | Recent Studies (post-2010) (fasentin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 11 | 0 | 10 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfieri, RR; Bonelli, MA; Caffarra, C; Cavazzoni, A; Fumarola, C; Galetti, M; Galvani, E; Generali, D; La Monica, S; Petronini, PG | 1 |
1 other study(ies) available for sorafenib and fasentin
| Article | Year |
|---|---|
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Anilides; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; Down-Regulation; Energy Metabolism; Female; Glucose; Glucose Transporter Type 1; Glycolysis; Humans; Inhibitory Concentration 50; Mechanistic Target of Rapamycin Complex 1; Mitochondria; Multiprotein Complexes; Neoplasm Proteins; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2013 |